The dermatology industry's psoriasis sector will continue to grow despite
patent expiries for key treatments, as impressive R&D spending reinforces
product pipelines, states the latest report from pharmaceutical industry
analysts GBI Research.
The company's latest study* predicts the psoriasis sector's global
revenue will maintain respectable growth over the next few years, climbing
from a 2011 total of $4.6 billion to $6 billion in 2018, at a Compound Annual
Growth Rate (CAGR) of 4%.
GBI Research attributes growth in the face of product expiries to the
relatively recent release of key treatments, such as Janssen Biotech's Stelara
in 2009, and several promising molecules including AIN457, tofacitinib, CF101
and anti-CD6 monoclonal antibody, which are currently in development and are
expected to be launched by 2014.
Additionally, the report highlights the growing global population as a key
factor determining psoriasis industry revenue - as the number of people
increases, so does the amount of those with psoriasis. The prevalence of
psoriasis was estimated to be 6.7 million people in 2011, but this is expected
to climb at a CAGR of 0.4%, reaching 6.9 million by the end of 2018.
Due to the more physically obvious and unpleasant aspects of psoriasis, those
afflicted are also more likely to seek medical help than people suffering from
conditions with less obvious symptoms, and as there is currently no cure,
patients must seek treatment for life.
The dermatology therapeutics market as a whole jumped from a 2004 value of
$11.4 billion to $15.8 billion in 2011. By 2018, GBI Research expects this
figure to reach $19.1 billion.
*Dermatology Therapeutics Market to 2018 - Novel Biologics Targeting Interleukin-17 Receptor Presents New Options in Psoriasis Treatment.
This report provides insights into the dermatology therapeutics market
including market forecasts up to 2018.
The report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GBI
Research's team of industry experts.
Table of Contents
Table of Contents
1. Table of Contents
1.1. List of Tables
1.2. List of Figures
2. Dermatology Therapeutics Market to 2018 - Introduction
3. Dermatology Therapeutics Market to 2018 - Market Overview
3.1. Revenue
3.2. Annual Cost of Treatment
3.3. Treatment Usage Pattern
3.3.1. Diseased Population
3.3.2. Treatment-Seeking Population
3.3.3. Diagnosed Population
3.3.4. Prescription Population
3.4. Recently Approved Product
3.4.1. Fabior (Tazarotene)
3.5. Key Trends
3.5.1. Potential New Treatment for Skin Diseases
3.5.2. Innovative Medicines Initiative Launched in Europe to Address
Antibiotic Resistance
4. Dermatology Therapeutics Market to 2018 - Geographical Landscape
4.1. Revenue by Country
4.2. The US
4.2.1. Revenue
4.2.2. Annual Cost of Treatment
4.2.3. Treatment Usage Pattern
4.3. Top Five Countries in Europe
4.3.1. Revenue
4.3.2. Annual Cost of Treatment
4.3.3. Treatment Usage Pattern
4.4. Japan
4.4.1. Revenue
4.4.2. Annual Cost of Treatment
4.4.3. Treatment Usage Pattern
5. Dermatology Therapeutics Market to 2018 - Therapeutic Landscape
5.1. Global Alopecia Therapeutics Market
5.1.1. Introduction
5.1.2. Revenue
5.1.3. Annual Cost of Treatment
5.1.4. Treatment Usage Pattern
5.1.5. Treatment Algorithm
5.1.6. Drivers and Restraints
5.2. Global Herpes Therapeutics Market
5.2.1. Introduction
5.2.2. Revenue
5.2.3. Annual Cost of Treatment
5.2.4. Treatment Usage Pattern
5.2.5. Treatment Algorithm
5.2.6. Drivers and Restraints
5.3. Global Psoriasis Therapeutics Market
5.3.1. Introduction
5.3.2. Revenue
5.3.3. Annual Cost of Treatment
5.3.4. Treatment Usage Pattern
5.3.5. Treatment Algorithm
5.3.6. Drivers and Restraints
5.4. Global Acne Therapeutics Market
5.4.1. Introduction
5.4.2. Revenue
5.4.3. Annual Cost of Treatment
5.4.4. Treatment Usage Pattern
5.4.5. Treatment Algorithm
5.4.6. Drivers and Restraints
5.5. Global Rosacea Disease Therapeutics Market
5.5.1. Introduction
5.5.2. Revenue
5.5.3. Annual Cost of Treatment
5.5.4. Treatment Usage Pattern
5.5.5. Treatment Algorithm
5.5.6. Drivers and Restraints
5.6. Global Atopic Dermatitis Therapeutics Market
5.6.1. Introduction
5.6.2. Revenue
5.6.3. Annual Cost of Treatment
5.6.4. Treatment Usage Pattern
5.6.5. Treatment Algorithm
5.6.6. Drivers and Restraints
6. Dermatological Therapeutics Market - Asia-Pacific Countries
6.1. India
6.1.1. Healthcare Overview
6.1.2. Regulatory Landscape
6.1.3. Market Overview
6.1.4. Key Trends
6.1.5. Company Analysis
6.1.6. Drivers and Restraints
6.2. China
6.2.1. Market Overview
6.2.2. Key Trends
6.3. Australia
6.3.1. Market Overview
6.3.2. Pricing and Reimbursement
7. Dermatological Therapeutics Market to 2018 - Pipeline Analysis
7.1. Introduction
7.1.1. Research and Development Pipeline - Alopecia
7.1.2. Research and Development Pipeline - Herpes
7.1.3. Research and Development Pipeline - Psoriasis
7.1.4. Research and Development Pipeline - Acne vulgaris
7.1.5. Research and Development Pipeline - Rosacea
7.1.6. Research and Development Pipeline - Atopic Dermatitis
7.2. Key R&D Trends
7.3. Promising Molecules - NDA Filed
7.3.1. LAS 41002
7.3.2. Low-Dose Duac
7.3.3. Acnex
7.4. Promising Molecules - Phase III
7.4.1. Zoster
7.4.2. ARYS-01
7.4.3. V212
7.4.4. CC-10004
7.4.5. CD07805/47
7.5. Promising Molecules - Phase II
7.5.1. EPB-348
7.5.2. AMG 827
7.5.3. V-101
7.5.4. MK-3222
8. Dermatology Therapeutics Market to 2018 - Competitive Landscape
Figure 85: Aesthetic Dermatology, Cosmetic and Reconstructive Plastic
Surgery Trends, the US, 2011
Figure 86: Aesthetic Dermatology, Cosmetic Plastic Surgery Demographic
Trends, the US, 2011
Figure 87: Aesthetic Dermatology, Drivers and Restraints, 2012
Figure 88: GBI Research Market Forecasting Model
Dermatology Therapeutics Market to 2018 - Novel Biologics Targeting Interleukin-17 Receptor Presents New Options in Psoriasis Treatment published by GBI Research in October 15, 2012. This report consists of Pages: 176 and the price starts from US $ 3500.
The contents of this page may be different from the latest version. Please contact us for details.
